Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance

Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine

(2015) Claudia Fiorini et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy

(2015) Bernhard Robl et al.   BMC CANCER

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Potential therapeutic targets inARID1A-mutated cancers

(2015) Benjamin G Bitler et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Biliary Tract Cancers: Finding Better Ways to Lump and Split

(2015) Robin K. Kelley et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets

(2015) Hwajeong Lee et al.   JOURNAL OF CLINICAL PATHOLOGY

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

HDAC inhibition impedes epithelial–mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer

(2015) M Ruscetti et al.   ONCOGENE

Histone Deacetylase Inhibitors Antagonize Distinct Pathways to Suppress Tumorigenesis of Embryonal Rhabdomyosarcoma

(2015) Terra Vleeshouwer-Neumann et al.   PLoS One

Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma

(2015) Daniela Sia et al.   Nature Communications

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors

(2015) J. Shen et al.   Cancer Discovery

Targeting CDK4 and CDK6: From Discovery to Therapy

(2015) C. J. Sherr et al.   Cancer Discovery

MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma

(2015) Sameer A. Dhayat et al.   PLoS One

Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition

(2015) Eleftherios P. Samartzis et al.   Oncotarget

Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets

(2014) Andrew X. Zhu et al.   ANNALS OF SURGICAL ONCOLOGY

A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation

(2014) Kimberly C Wiegand et al.   BMC CANCER

The emerging roles of ARID1A in tumor suppression

(2014) Ren-Chin Wu et al.   CANCER BIOLOGY & THERAPY

Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway

(2014) Maolan Li et al.   NATURE GENETICS

New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing

(2014) J. S. Ross et al.   ONCOLOGIST

Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer

(2013) Tjalling Bosse et al.   MODERN PATHOLOGY

Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma

(2013) Hsien-Neng Huang et al.   MODERN PATHOLOGY

Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers

(2013) Waraporn Chan-on et al.   NATURE GENETICS

Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas

(2013) Yuchen Jiao et al.   NATURE GENETICS

Signaling through cyclin D-dependent kinases

(2013) Y J Choi et al.   ONCOGENE

Exome sequencing of liver fluke–associated cholangiocarcinoma

(2012) Choon Kiat Ong et al.   NATURE GENETICS

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

(2012) Jonathan Ledermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

ARID1A Mutations in Cancer: Another Epigenetic Tumor Suppressor?

(2012) Jennifer N. Wu et al.   Cancer Discovery

ARID1A, a Factor That Promotes Formation of SWI/SNF-Mediated Chromatin Remodeling, Is a Tumor Suppressor in Gynecologic Cancers

(2011) B. Guan et al.   CANCER RESEARCH

Loss of ARID1A-Associated Protein Expression is a Frequent Event in Clear Cell and Endometrioid Ovarian Cancers

(2011) William J. Lowery et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2

(2010) Hyunho Yoon et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Histone Deacetylase Inhibitors

(2009) Xujun Ma et al.   DRUGS

Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing

(2009) Andreas Gnirke et al.   NATURE BIOTECHNOLOGY

Systemic Therapy for Biliary Tract Cancers

(2008) A. F. Hezel et al.   ONCOLOGIST

Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines

(2008) Li-Ning Xu et al.   WORLD JOURNAL OF GASTROENTEROLOGY